PE55694A1 - Medicamentos - Google Patents

Medicamentos

Info

Publication number
PE55694A1
PE55694A1 PE1993231837A PE23183793A PE55694A1 PE 55694 A1 PE55694 A1 PE 55694A1 PE 1993231837 A PE1993231837 A PE 1993231837A PE 23183793 A PE23183793 A PE 23183793A PE 55694 A1 PE55694 A1 PE 55694A1
Authority
PE
Peru
Prior art keywords
combination
medicines
naftoquinone
cycllohexyl
atovacuone
Prior art date
Application number
PE1993231837A
Other languages
English (en)
Inventor
Edward Gutteridge Winston
Brian Ashton Hutchinson David
Susan Latter Victoria
Pudney Mary
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10725687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE55694(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of PE55694A1 publication Critical patent/PE55694A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA FORMULACION FARMACEUTICA QUE COMPRENDE LA COMBINACION, YA SEA CONCOMITANTEMENTE O SECUENCIALMENTE DE: (A) 2-[4-(4-CLOROFENIL)CICLOHEXIL]-3-HIDROXI-1,4-NAFTOQUINONA LLAMADA TAMBIEN ATOVACUONA DE FORMULA II ,Y (B) PROGUANIL ; QUE POR FORMAR UNA COMBINACION SINERGICA TIENE MAYOR ACTIVIDAD ANTIPARASITARIA - ANTIPROTOZOARIA, PUDIENDO SER UTIL EN EL TRATAMIENTO DE LA MALARIA, TOXOPLASMOSIS E INFECCIONES PRODUCIDAS POR P. CARINII
PE1993231837A 1992-11-26 1993-11-25 Medicamentos PE55694A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929224739A GB9224739D0 (en) 1992-11-26 1992-11-26 Medicaments

Publications (1)

Publication Number Publication Date
PE55694A1 true PE55694A1 (es) 1995-01-25

Family

ID=10725687

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1993231837A PE55694A1 (es) 1992-11-26 1993-11-25 Medicamentos

Country Status (38)

Country Link
US (3) US5998449A (es)
EP (1) EP0670719B1 (es)
JP (1) JP3768231B2 (es)
KR (1) KR100294802B1 (es)
CN (1) CN1087935C (es)
AP (1) AP517A (es)
AT (1) ATE191340T1 (es)
AU (1) AU685408B2 (es)
BG (1) BG62595B1 (es)
CA (1) CA2150234E (es)
CY (1) CY2193B1 (es)
CZ (2) CZ289171B6 (es)
DE (1) DE69328307T2 (es)
DK (1) DK0670719T3 (es)
ES (1) ES2145114T3 (es)
GB (1) GB9224739D0 (es)
GR (1) GR3033745T3 (es)
HK (1) HK1004468A1 (es)
HU (1) HU225918B1 (es)
IL (1) IL107755A (es)
MX (1) MX9307402A (es)
MY (1) MY114241A (es)
NO (1) NO313225B1 (es)
NZ (1) NZ257901A (es)
OA (1) OA10352A (es)
PE (1) PE55694A1 (es)
PL (1) PL174323B1 (es)
PT (1) PT670719E (es)
RO (1) RO119280B1 (es)
RU (1) RU2108092C1 (es)
SA (1) SA93140434B1 (es)
SG (1) SG45387A1 (es)
SI (1) SI9300614A (es)
SK (1) SK281559B6 (es)
TW (1) TW253835B (es)
UA (1) UA45948C2 (es)
WO (1) WO1994012164A1 (es)
ZA (1) ZA938832B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9424013D0 (en) * 1994-11-29 1995-01-18 Wellcome Found Medicaments
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
GB9822681D0 (en) * 1998-10-16 1998-12-09 Vitabiotics Ltd Method of treatment
US6413993B1 (en) 1999-04-09 2002-07-02 Smithkline Beecham Corporation Combination preparation for treating malaria
US7104076B2 (en) * 2004-06-24 2006-09-12 Carrier Corporation Lubricant return schemes for use in refrigerant cycle
ITMI20070941A1 (it) * 2007-05-09 2008-11-10 Chimico Internazi0Nale S P A L Procedimento per la preparazione di naftochinoni trans2,3-disostituiti
EP2467358B1 (en) * 2009-08-20 2014-07-23 IPCA Laboratories Limited Novel complex for treatment and/or prophylaxis of parasitic infections
US20180055835A1 (en) 2016-08-25 2018-03-01 Immune Therapeutics Inc. Method for Treating And Preventing Protozoal Infections

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2533648A (en) * 1949-03-05 1950-12-12 Joseph H Warburg Circular saw making
NL6411993A (es) * 1963-10-18 1965-04-20
US3347830A (en) * 1964-07-30 1967-10-17 Grace W R & Co Process of polymerizing formaldehyde
GB1141735A (en) * 1966-11-23 1969-01-29 Pfizer & Co C Pharmaceutical anti-tumor composition
NL6817526A (es) * 1968-01-24 1969-07-28
US3655699A (en) * 1970-03-02 1972-04-11 Pfizer Analogues of lapachol as antitumor agents
DE2601458A1 (de) * 1975-01-20 1976-07-22 Ciba Geigy Ag Loesliche, von phenylindandiaminen abgeleitete polyamide
IL56013A (en) * 1977-11-22 1983-06-15 Wellcome Found 2-cycloalkyl-3-hydroxy-1,4-naphthoquinone derivatives,their preparation and therapeutic compositions containing them
US4485116A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
US4485117A (en) * 1981-10-16 1984-11-27 Hudson Alan T Antiprotozoal compounds
GB8310141D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Naphthoquinone derivatives
US5053432A (en) * 1983-04-14 1991-10-01 Burroughs Wellcome Co. Naphthoquinone derivatives
GB8310140D0 (en) * 1983-04-14 1983-05-18 Wellcome Found Antiprotozoal agents
JPS59196467A (ja) * 1983-04-23 1984-11-07 Nissan Motor Co Ltd 車輪速及びまたは車輪加減速度検出方法
SG23618G (en) * 1988-08-16 1995-09-18 Wellcome Found Naphthoquinones for the treatment and prophylaxis of pneumocystis carinii infections
US5206268A (en) * 1988-08-16 1993-04-27 Burroughs Wellcome Co. Medicaments
US5225184A (en) * 1988-08-16 1993-07-06 Burroughs Wellcome Co. Medicaments
GB8819477D0 (en) * 1988-08-16 1988-09-21 Wellcome Found Medicaments
GB8921516D0 (en) * 1989-09-22 1989-11-08 Wellcome Found Medicaments
GB8923254D0 (en) * 1989-10-16 1989-12-06 Wellcome Found Medicaments
US5014737A (en) * 1989-11-13 1991-05-14 Allan Berman Quartz integrated trough/sump recirculating filtered high-purity chemical bath
GB9121316D0 (en) * 1991-10-09 1991-11-20 Wellcome Found Heterocyclic compounds
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
GB9226905D0 (en) * 1992-12-24 1993-02-17 Wellcome Found Pharmaceutical preparation
US5529994A (en) * 1993-05-05 1996-06-25 Palo Alto Medical Foundation Treatment for toxoplasmosis
CA2138643A1 (en) * 1993-05-05 1994-11-10 Jack S. Remington Use of rifamycin derivatives for the manufacture of a medicament for the treatment of toxoplasmosis
US5733932A (en) * 1995-01-06 1998-03-31 The Picower Institute For Medical Research Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
US5827543A (en) * 1995-12-07 1998-10-27 The Procter & Gamble Company Methods and compositions for the prevention and treatment of urogenital disorders
US5744168A (en) * 1995-12-07 1998-04-28 The Procter & Gamble Company Methods and compositions for the prevention and treatment of gastrointestinal disorders
US5747476A (en) * 1996-07-17 1998-05-05 Mortar & Pestle Veterinary Pharmacy, Inc. Treatment of equine protozoal myeloencephalitis
ZA983331B (en) * 1997-05-01 1998-10-27 Allegheny University Of The He Method for treating protozoal infections
AUPO821097A0 (en) * 1997-07-25 1997-08-14 Cultor Ltd. A prophylactic
DE19737463A1 (de) * 1997-08-28 1999-03-04 Hoechst Marion Roussel De Gmbh Verwendung von Inhibitoren des Natrium-Wasserstoff-Austauschers zur Herstellung eines Arzneimittels zur Behandlung von Erkrankungen, die durch Protozoen verursacht werden
US6413993B1 (en) * 1999-04-09 2002-07-02 Smithkline Beecham Corporation Combination preparation for treating malaria

Also Published As

Publication number Publication date
HUT71346A (en) 1995-11-28
EP0670719A1 (en) 1995-09-13
BG62595B1 (bg) 2000-03-31
JPH08503938A (ja) 1996-04-30
SI9300614A (en) 1994-06-30
KR100294802B1 (ko) 2001-09-17
US5998449A (en) 1999-12-07
NO313225B1 (no) 2002-09-02
RO119280B1 (ro) 2004-07-30
DK0670719T3 (da) 2000-07-31
PL174323B1 (pl) 1998-07-31
GR3033745T3 (en) 2000-10-31
CZ289692B6 (cs) 2002-03-13
CN1087935C (zh) 2002-07-24
CY2193B1 (en) 2002-11-08
SA93140434B1 (ar) 2004-09-01
BG99656A (bg) 1996-04-30
AU5532294A (en) 1994-06-22
CZ289171B6 (cs) 2001-11-14
ATE191340T1 (de) 2000-04-15
SG45387A1 (en) 1998-01-16
CN1091632A (zh) 1994-09-07
US6166046A (en) 2000-12-26
DE69328307T2 (de) 2000-10-26
AP9300592A0 (en) 1994-01-31
SK57095A3 (en) 1996-05-08
MY114241A (en) 2002-09-30
OA10352A (en) 2001-10-22
ZA938832B (en) 1995-05-25
ES2145114T3 (es) 2000-07-01
CA2150234A1 (en) 1994-06-09
EP0670719B1 (en) 2000-04-05
UA45948C2 (uk) 2002-05-15
MX9307402A (es) 1994-07-29
IL107755A0 (en) 1994-02-27
HU225918B1 (en) 2007-12-28
GB9224739D0 (en) 1993-01-13
NO951995L (no) 1995-07-03
TW253835B (es) 1995-08-11
AP517A (en) 1996-08-23
CZ119295A3 (en) 1995-11-15
WO1994012164A1 (en) 1994-06-09
CA2150234C (en) 2001-01-16
PL309222A1 (en) 1995-10-02
CA2150234E (en) 2005-03-22
PT670719E (pt) 2000-09-29
JP3768231B2 (ja) 2006-04-19
AU685408B2 (en) 1998-01-22
RU2108092C1 (ru) 1998-04-10
HK1004468A1 (en) 1998-11-27
NO951995D0 (no) 1995-05-19
IL107755A (en) 2000-10-31
HU9501537D0 (en) 1995-07-28
SK281559B6 (sk) 2001-05-10
DE69328307D1 (de) 2000-05-11
US6291488B1 (en) 2001-09-18
NZ257901A (en) 1997-01-29

Similar Documents

Publication Publication Date Title
ECSP045102A (es) Formulación farmacéutica que contiene 3-(3-dimetilamino-1-etil-2-metil-propil)fenol y proporciona una liberación retardada del ingrediente activo
BR0015605A (pt) Composição e uso
UY25055A1 (es) Formulaciones farmacéuticas que contienen voriconazol
MX9202407A (es) Composicion farmaceutica que contiene un compuesto de alilamina como el agente activo y proceso para su preparacion.
AR030068A1 (es) Composiciones farmaceuticas para el tratamiento de condiciones dolorosas, inflamatorias y ulcerosas de superficies epiteliales humedas como por ejemplo mucositis, estomatitis y sindrome de behcet
MX9202328A (es) Composicion farmaceutica local que contiene un compuesto alilamina como el agente activo.
CL2012000348A1 (es) Metodo para tratar o reducir la gravedad de la osteoporosis u osteopenia en un paciente que comprende administrarle el compuesto n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolina-3-carboxamida o una sal del mismo; composicion farmaceutica.
KR870005637A (ko) 약물 데포
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
CO4290417A1 (es) Nuevas benzoilguanidinas como medicamentos y su preparacion .
AR032912A1 (es) Formulacion farmaceutica
CO4230155A1 (es) Agentes sinergicos para combatir insectos y acaros .
PE55694A1 (es) Medicamentos
AR086688A2 (es) Composicion farmaceutica con excipiente liquido modificado, un metodo para producir una composicion farmaceutica y el uso de dicha composicion para preparar un medicamento
AR032872A1 (es) Composicion para aclarar la piel y el metodo de aplicacion
PE61699A1 (es) Composicion farmaceutica de lamivudina
ES2144452T3 (es) Medicamento para el tratamiento de infecciones protozoarias provocadas por babesia.
ES2033181B1 (es) Una tableta o capsula de herbicida para su aplicacion en arrozales.
ES2128353T3 (es) Composicion topica que contiene penciclovir.
AR030647A1 (es) Composicion farmaceutica con actividad de agua especifica
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie
DK93091A (da) Laegemidler til behandling af toxoplasmose
DK0652704T3 (da) Anvendelse af ethercarboxylsyrer som kimdræbende stoffer.
BR0009778A (pt) Composições antifúngicas de pseudomicina e métodos para utilização das mesmas
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term